Analyst Price Target is $10.67
▲ +319.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for NLS Pharmaceutics in the last 3 months. The average price target is $10.67, with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 319.95% upside from the last price of $2.54.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in NLS Pharmaceutics.
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland.